Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Rodenhuis

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantationM W Dercksen, S Rodenhuis, M K Dirkson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialA Le Cesne, J Y Blay, I Judson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 17, 2012
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapyB B Koolen, M J T F D Vrancken Peeters, J Wesseling, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 6, 2008
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]M E Straver, J C van Adrichem, E J Th Rutgers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2006
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancerS Rodenhuis, M Bontenbal, Q G C M van Hoesel, et al.
British Journal of Cancer|October 24, 2013
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerL S Rigter, C E Loo, S C Linn, et al.
Bone Marrow Transplantation|July 16, 2008
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patientsP Nieboer, E G E de Vries, N H Mulder, et al.
British Journal of Cancer|November 8, 2006
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapyJ Hannemann, P Kristel, H van Tinteren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyN Penel, G D Demetri, J Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2010
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsM A Vollebergh, E H Lips, P M Nederlof, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Subsets of CD34+ cells and rapid hematopoietic recovery after peripheral-blood stem-cell transplantationM W Dercksen, S Rodenhuis, M K Dirkson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trialA Le Cesne, J Y Blay, I Judson, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 17, 2012
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapyB B Koolen, M J T F D Vrancken Peeters, J Wesseling, et al.
Nederlands Tijdschrift Voor Geneeskunde|December 6, 2008
[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy]M E Straver, J C van Adrichem, E J Th Rutgers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2006
Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancerS Rodenhuis, M Bontenbal, Q G C M van Hoesel, et al.
British Journal of Cancer|October 24, 2013
Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancerL S Rigter, C E Loo, S C Linn, et al.
Bone Marrow Transplantation|July 16, 2008
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patientsP Nieboer, E G E de Vries, N H Mulder, et al.
British Journal of Cancer|November 8, 2006
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapyJ Hannemann, P Kristel, H van Tinteren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2012
Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapyN Penel, G D Demetri, J Y Blay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 8, 2010
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsM A Vollebergh, E H Lips, P M Nederlof, et al.
Pageof 15